United States Patent 7,488,827 Landscape: What Is Claimed, Claim Scope Boundaries, and How Competing Filings Fit the Patent Estate
Executive summary: US 7,488,827 claims a specific bromide salt of a bicyclic quaternary ammonium compound, plus pharmaceutical compositions (including inhalation-ready dry powder formulations) limited to specified anion classes and, in dependent claims, lactose as the carrier. For freedom-to-operate, the operative question is whether a competitor’s active ingredient is the same cation with the same anion (bromide or iodide singled out) or an alternative anion within the enumerated list. If the active cation matches and the anion is outside the enumerated anion set, infringement risk under these claims is reduced but not eliminated if equivalents or other related patents cover non-enumerated salts, hydrates, polymorphs, or alternative inhalation carriers.
What is US Patent 7,488,827 and what compound does it claim?
Direct answer: US 7,488,827 is centered on the compound:
4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide, and composition claims that reuse that compound plus a pharmaceutically acceptable carrier.
What is the claimed chemical identity
The core cation is the bicyclic quaternary ammonium scaffold:
4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane
Claim 1 specifies the bromide salt form by naming “bromide” as the anion.
How broad are the compound claims as written
The independent claim 1 is narrow at the active-ingredient level: it specifies the bromide salt. There is no generic “pharmaceutically acceptable salt” in claim 1; that breadth is introduced via claims 3-10 using a generic “X is a pharmaceutically acceptable anion” plus dependent narrowing to a defined anion roster.
What are the independent claims in US 7,488,827 and what is their legal scope?
Direct answer: The key independent claims are:
- Claim 1: the bromide compound (active ingredient)
- Claim 2: a pharmaceutical composition comprising that bromide compound plus a pharmaceutically acceptable carrier
Claim 1 scope (active ingredient infringement trigger)
Claim 1 requires all structural elements:
- The exact cation scaffold (the specified bicyclic quaternary ammonium structure with hydroxy and diphenylmethyl and phenylmethyl oxyethyl substituents)
- The anion as bromide
Practical implication: A competitor using the same cation but a different salt (e.g., chloride, acetate, sulfate, or iodide) is outside claim 1 literally, but could still fall under claims 3-10 if the salt is within the enumerated anion list and if other claim elements match.
Claim 2 scope (composition infringement trigger)
Claim 2 covers:
- The bromide compound (as the active)
- A pharmaceutically acceptable carrier
Practical implication: Claim 2 is generally broad on carrier selection. It does not, by itself, require inhalation or a dry powder. That narrower context appears in dependent claims 11-18.
What does “X is a pharmaceutically acceptable anion” add to the claim set?
Direct answer: Claims 3-10 expand coverage from a single bromide salt to a selected list of pharmaceutically acceptable anions for the same cation.
Claim 3 framework
- Claim 3: compound wherein X is a pharmaceutically acceptable anion
This claim is broad as to anion class, but it is bounded by later dependent claims (and, in claim-construction terms, “pharmaceutically acceptable” still limits to salts usable in pharmaceuticals).
Claim 4 anion roster
- Claim 4: enumerates anions including:
chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate, p-toluenesulfonate
Practical implication: If an accused product is the same cation with one of the listed anions, it is mapped into claim 3 and can be pinned by the narrower dependent claim 4, 5 (bromide), or 6 (iodide) depending on the anion used.
Claims 5 and 6
- Claim 5: anion is bromide
- Claim 6: anion is iodide
Practical implication: These provide explicit coverage for bromide (claim 1 already does) and iodide. If a competitor’s active ingredient is the iodide salt, the claim set includes a direct dependent anchor.
What formulations are protected: inhalation and dry powder carrier limits?
Direct answer: The patent includes composition claims specifically targeting oral or nasal inhalation, and dependent claims limiting to inhalation via specified device classes plus dry powder formats and lactose as carrier.
Claim 11 and 12: route and device
- Claim 11: composition suitable for administration by oral or nasal inhalation
- Claim 12: inhalation via a medicament dispenser selected from:
- reservoir dry powder inhaler
- multi-dose dry powder inhaler
- metered dose inhaler
Scope boundary: Claim 12 narrows the inhalation context to particular device categories, which can matter for infringement analysis if accused products are marketed or configured around different dispenser types.
Claim 13 and 14: dry powder and lactose
- Claim 13: composition is a dry powder composition
- Claim 14: pharmaceutically acceptable carrier is lactose
Scope boundary: Claim 14 is carrier-specific. A dry powder inhalation product using a non-lactose carrier system would not meet the lactose limitation in claim 14.
Claims 15-18 mirror the inhalation and lactose concepts for claim 7
- Claim 15: composition suitable for oral or nasal inhalation
- Claim 16: inhalation via the same listed dispenser categories
- Claim 17: composition is a dry powder composition
- Claim 18: carrier is lactose
Practical implication: Claims 13-14 tie to the broader claim 2 (bromide). Claims 15-18 tie to claim 7 (anion-variable salt framework). That makes the lactose + dry powder limitation potentially relevant even if the salt is not bromide, as long as it falls within claim 7’s anion structure and then claims 15-18 are met.
How many different product variants does the claim set cover?
Direct answer: The claim set covers:
- Active salt variants: bromide plus iodide explicitly, and a defined set of other enumerated anions through claims 3-4
- Salt inclusion dependent claims: bromide and iodide are singled out
- Dosage form variants: inhalation (oral or nasal), including dry powder, with lactose carrier limitation in dependent claims
Variant matrix (as claimed)
| Claim element |
What it allows |
What it excludes (by structure/wording) |
| Cation |
the specific azoniabicyclo scaffold with specified substituents |
any other cation scaffold |
| Anion for claim 1 |
bromide |
non-bromide anions |
| Anion for claims 3-4 |
one of the enumerated anions |
anions not in the enumerated list (unless “pharmaceutically acceptable anion” is used without narrowing, but dependent claims still require membership) |
| Oral/nasal inhalation |
yes in claims 11 and 15 |
non-inhalation formulations (unless asserted under claim 2 or claim 7 carrier-only claims) |
| Dry powder |
yes in claims 13 and 17 |
liquid, solution, aerosol formats (unless separately covered by other claims not provided) |
| Lactose carrier |
yes in claims 14 and 18 |
dry powders using other carriers excude literal compliance with those dependent claims |
What does “bromide vs iodide vs other enumerated anions” mean for infringement?
Direct answer: The claim text creates three practical infringement lanes:
- Bromide products are directly captured by claim 1 and claim 2, and also by inhalation and lactose dependent claims (11-14).
- Iodide products are not claim 1, but they are covered via the generic anion claims (3) and the iodide-dependent claim (6), plus any matching composition/inhalation/dry powder/lactose limitations under claims 7 and 15-18.
- Other enumerated anion products (chloride, acetate, sulfate, etc.) are captured through claim 3 + claim 4 and then via the corresponding composition and formulation dependent chains.
Lane mapping
- Claim 1/2 chain: only bromide salt
- Claim 3/4 + Claim 7 chain: same cation with enumerated anions; includes iodide through claim 6
- Inhalation chain: depends on whether accused product is an inhalation formulation (claims 11/15)
- Dry powder + lactose chain: literal carrier limitation in claims 14/18
What patent estate risks exist if a generic or competitor uses a different salt form?
Direct answer: Literal infringement of the provided claims depends heavily on salt identity and carrier selection. If a competitor uses a non-enumerated anion (not in claim 4 list) and avoids lactose as carrier in the dry powder inhalation context, it can be positioned to argue non-infringement on literal claim elements.
Salt-switch strategy and its limits
- Switch to non-listed anions: reduces risk for claims requiring the enumerated anion list (claim 4).
- Switch from lactose to non-lactose excipients: reduces risk for dependent claims 14 and 18.
- But: if other patents in the broader family (not provided here) cover alternate salts, polymorphs, hydrates, or non-lactose carrier systems, the risk can re-emerge.
This analysis is constrained to the specific claims provided for US 7,488,827.
How does the claim set constrain inhalation product design?
Direct answer: The inhalation-related dependent claims restrict the protected product configurations to those that match (i) route (oral or nasal inhalation), (ii) dispenser class (for claim 12/16), (iii) dry powder format (claim 13/17), and (iv) lactose carrier (claim 14/18).
Device-type limitation practical impact
Claims 12 and 16 specify dispenser categories. If a product is administered through a dispenser type outside those listed categories, it may avoid those dependent claims, even if it remains an oral/nasal inhalation dry powder.
Carrier limitation practical impact
Claim 14/18 are the most design-constraining limitations because they name lactose as the carrier for dry powder inhalation compositions.
What is the overall strength of these claims for enforcing an exclusivity moat?
Direct answer: Enforceability is strongest for products that:
- use the exact cation and a listed anion, and
- market or practice oral/nasal inhalation, and
- use dry powder lactose in the relevant embodiments (dependent claims)
It is weaker against products that:
- use a different cation,
- use a non-enumerated anion, or
- use dry powder inhalation with non-lactose carriers
Claim architecture observation
The patent separates:
- active ingredient identity (claim 1),
- composition with broad carrier (claim 2 and claim 7),
- inhalation route/device qualifiers (claims 11-12 and 15-16),
- dry powder and lactose carrier qualifiers (claims 13-14 and 17-18)
That architecture supports targeted enforcement against specific commercial product profiles rather than a single universal barrier.
What generic entry scenarios are implicated by these claims?
Direct answer: Any “generic” or follow-on using the same active cation and the bromide salt is exposed across claim 1/2 and can be exposed further if its formulation matches the inhalation/dry powder/lactose limitations. Iodide and other enumerated anion salts are exposed through the anion-generic pathway in claims 3-4 and claim 7 plus dependent formulation claims.
Scenario mapping
- Same cation + bromide + inhaled dry powder + lactose: highest exposure (claims 1, 2, 11-14)
- Same cation + bromide + inhaled but non-dry-powder: exposure likely for claims 1-2; inhalation-dependent dependent claims not necessarily met
- Same cation + iodide + inhaled dry powder + lactose: exposure for claim 3/6 and claims 7/15-18
- Same cation + enumerated anion but non-lactose dry powder: reduces exposure to lactose-dependent claims 14/18 (still exposed to broader composition claims 2/7)
Which competitors would be most at risk if their products match the claimed anion and inhalation format?
Direct answer: Companies most at risk are those commercializing (or seeking to commercialize) inhalation products containing:
- the specific azoniabicyclo cation, and
- one of the enumerated anions (especially bromide or iodide), and
- dry powder inhalation formulations using lactose
Scope limitation: Specific company mapping requires the patent’s publication/application family data, Orange Book listings, and FDA label details. None are included in the provided input.
Key Takeaways
- US 7,488,827 is built around a single cation scaffold with claims tailored to bromide (claim 1) and an enumerated anion set (claims 3-4), including iodide (claim 6).
- Composition coverage is broad on carriers in the base claims (claim 2 and claim 7), but narrows in dependent claims to oral/nasal inhalation, specified dispenser categories, dry powder, and lactose.
- The main design-risk knobs for competitors are:
- Anion identity (bromide/iodide/claim-4 list)
- Dosage format (dry powder inhalation)
- Carrier selection (lactose for the dependent claims)
FAQs
1) Does US 7,488,827 cover non-bromide salts?
Yes. Claims 3-4 cover the same cation with “X” as a pharmaceutically acceptable anion, with dependent claim 4 enumerating specific allowed anions including chloride and iodide.
2) Are iodide salts covered even though claim 1 lists bromide?
Yes. Claim 6 explicitly covers the iodide anion, within the “X is a pharmaceutically acceptable anion” structure of claims 3-4.
3) Does the patent protect all inhalation formulations?
No. Inhalation protection is tied to dependent claims requiring oral/nasal inhalation and, in further dependent claims, specified dispenser types and dry powder format.
4) Can a lactose-free dry powder inhalation avoid the narrowest formulation claims?
Yes for the lactose-dependent dependent claims (14 and 18). A product not using lactose in the claimed dry powder context avoids those specific limitations.
5) What is the most direct infringement path under the provided claims?
A product using the same cation with bromide (claim 1/2) and, if inhaled, matching the dependent limitations for oral/nasal inhalation, dry powder, and lactose (claims 11-14).
References
- US Patent 7,488,827 (claims as provided in prompt).
